Replies to post #15791 on NorthWest Biotherapeutics Inc (NWBO)

[gnawkz]

Hi Dok,

I read that slide differently.

Based on the title, "The 7 Biggest Misunderstanding of Benefits Assessment in Germany”, I interpreted this slide as a list of all misconceptions. Orphan drugs being exempted from benefit assessment is one of the key misconception that people typically walk away with. Based upon that interpretation, the August 2014 timeframe does not make sense and it should be the Feb 2015 timeframe.

[Evaluate]

Oops ... this post was supposed to be in reply to Gnawz post 15796.

But slide 16 includes a note:

Abbreviated assessment for orphan drugs

I agree that slide 23 seems to indicate that it is a misconception that

Orphan drugs are exempted from benefit assessment

but slide 16 appears to indicate that even though orphan drugs are not exempted from benefit assessment, that they do enjoy an abbreviated assessment.


Additionally, did you see that Slide 17 indicates:

Overall process of benefit assessment and price negotiation takes about 12 months –
plus about 12 months of preparation

So: perhaps somewhere between 6 to 12 months total for benefit assessment + price negotiation? Hopefully this is not "in addition to "12 months of preparation" (= month Minus 12 to month Zero)?

Perhaps someone should contact:

Ecker + Ecker GmbH . Warburgstraße 50 . 20354 Hamburg . Germany. Phone: [phone] . E-Mail: [e-mail] . www.ecker-ecker.de

...... and try to get to the bottom of this? (or could one possibly get in trouble doing this by risk of obtaining "insider information"?).